Dena Almeida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dena Almeida has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Katherine A. Hajjar
Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, New York
3 shared publications - Bernhard Kühn
Weill Cornell Medical College, Cornell University 1 Department of Pediatrics New York City, NY
1 shared publication - Brendan Lo
Weill Cornell Medical College, Cornell University 1 Department of Pediatrics New York City, NY
1 shared publication - Brian K. Panama
Physiology and Biophysics, The State University of New York, University at Buffalo 4 , Buffalo, NY
1 shared publication - Chendong Pan
Department of Ophthalmology, Weill Cornell Medicine, Margaret Dyson Vision Research Institute, New York, NY 10065
1 shared publication Christopher M. Lewarchik
Richard King Mellon Foundation Institute for Pediatric Research, UPMC Children’s Hospital of Pittsburgh 2 Division of Cardiology, and Institute for Pediatric Heart Regeneration and Therapeutics Pittsburgh, PA
1 shared publication
Latest Publications
- 25 June 2026
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 225 (8)
Sequential changes in calcium transients during M phase regulate cardiomyocyte proliferation
Heart muscle growth and regeneration require the proliferation of cardiomyocytes. Rapid pulsatile increases in cytosolic Ca2+ concentration, called calcium transients (CaTs), trigger cardiomyocyte contractions, but how cardiomyocytes adapt Ca2+ signaling during proliferation is largely unknown. Here, we show that cardiomyocyte proliferation requires changes in Ca2+ signaling. Cardiomyocytes undergo a sequence of CaT changes during M phase: CaT amplitudes begin to decline in prometaphase, reach a minimum in metaphase, rise during anaphase, and return to the original state in daughter cardiomyocytes. Spindle poles show decreased Ca2+ levels during prometaphase and metaphase. Localized reduction of Ca2+ levels at spindle poles is mediated by dynein 1–dependent SERCA2a accumulation. Active cyclin-dependent kinase 1 (CDK1) induces both the decrease in CaT amplitudes and the accumulation of SERCA2a at the spindle poles, whereas CDK1 inhibition reverses these effects. Forcing an increase in cytosolic Ca2+ levels by blocking SERCA2a during prometaphase and metaphase disrupts mitosis and produces binucleated cardiomyocytes, underscoring the essential role of Ca2+ signaling changes for cardiomyocyte proliferation.
- 25 June 2026
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 225 (8)
Sequential changes in calcium transients during M phase regulate cardiomyocyte proliferation
Heart muscle growth and regeneration require the proliferation of cardiomyocytes. Rapid pulsatile increases in cytosolic Ca2+ concentration, called calcium transients (CaTs), trigger cardiomyocyte contractions, but how cardiomyocytes adapt Ca2+ signaling during proliferation is largely unknown. Here, we show that cardiomyocyte proliferation requires changes in Ca2+ signaling. Cardiomyocytes undergo a sequence of CaT changes during M phase: CaT amplitudes begin to decline in prometaphase, reach a minimum in metaphase, rise during anaphase, and return to the original state in daughter cardiomyocytes. Spindle poles show decreased Ca2+ levels during prometaphase and metaphase. Localized reduction of Ca2+ levels at spindle poles is mediated by dynein 1–dependent SERCA2a accumulation. Active cyclin-dependent kinase 1 (CDK1) induces both the decrease in CaT amplitudes and the accumulation of SERCA2a at the spindle poles, whereas CDK1 inhibition reverses these effects. Forcing an increase in cytosolic Ca2+ levels by blocking SERCA2a during prometaphase and metaphase disrupts mitosis and produces binucleated cardiomyocytes, underscoring the essential role of Ca2+ signaling changes for cardiomyocyte proliferation.
- Open Access
- 19 March 2026
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 3 (2)
Sepsis-triggered proteolysis of profibrinolytic annexin A2 associated with microvasculopathy-related organ dysfunction
- 19 March 2026
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 3 (2)
Open AccessSepsis-triggered proteolysis of profibrinolytic annexin A2 associated with microvasculopathy-related organ dysfunction
- 15 November 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (47)
Lipofuscin causes atypical necroptosis through lysosomal membrane permeabilization
Significance: Retinal lipofuscin causes retinal pigment epithelium cell death in Stargardt and potentially dry–Age-Related Macular Degeneration (AMD). The current dogma is that lipofuscin’s cytotoxicity results from the light-triggered decomposition of its lipid-bisretinoids leading to apoptosis. However, antiapoptotic antioxidants or light-blocking lenses are not effective to stop degeneration in Stargardt and most AMD patients. Here, we show that lipofuscin forms aggregates in lysosomes, which trigger lysosomal membrane permeabilization and subsequent atypical necroptosis. We provide evidence that necrosulfonamide, necrostatin-7, and arimoclomol can effectively control this lethal cascade.
- 15 November 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (47)
Lipofuscin causes atypical necroptosis through lysosomal membrane permeabilization
Significance: Retinal lipofuscin causes retinal pigment epithelium cell death in Stargardt and potentially dry–Age-Related Macular Degeneration (AMD). The current dogma is that lipofuscin’s cytotoxicity results from the light-triggered decomposition of its lipid-bisretinoids leading to apoptosis. However, antiapoptotic antioxidants or light-blocking lenses are not effective to stop degeneration in Stargardt and most AMD patients. Here, we show that lipofuscin forms aggregates in lysosomes, which trigger lysosomal membrane permeabilization and subsequent atypical necroptosis. We provide evidence that necrosulfonamide, necrostatin-7, and arimoclomol can effectively control this lethal cascade.
- Open Access
- 10 July 2017
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 214 (9) , 2535-2545
Annexin A2 supports pulmonary microvascular integrity by linking vascular endothelial cadherin and protein tyrosine phosphatases
Relative or absolute hypoxia activates signaling pathways that alter gene expression and stabilize the pulmonary microvasculature. Alveolar hypoxia occurs in disorders ranging from altitude sickness to airway obstruction, apnea, and atelectasis. Here, we report that the phospholipid-binding protein, annexin A2 (ANXA2) functions to maintain vascular integrity in the face of alveolar hypoxia. We demonstrate that microvascular endothelial cells (ECs) from Anxa2−/− mice display reduced barrier function and excessive Src-related tyrosine phosphorylation of the adherens junction protein vascular endothelial cadherin (VEC). Moreover, unlike Anxa2+/+ controls, Anxa2−/− mice develop pulmonary edema and neutrophil infiltration in the lung parenchyma in response to subacute alveolar hypoxia. Mice deficient in the ANXA2-binding partner, S100A10, failed to demonstrate hypoxia-induced pulmonary edema under the same conditions. Further analyses reveal that ANXA2 forms a complex with VEC and its phosphatases, EC-specific protein tyrosine phosphatase (VE-PTP) and Src homology phosphatase 2 (SHP2), both of which are implicated in vascular integrity. In the absence of ANXA2, VEC is hyperphosphorylated at tyrosine 731 in response to vascular endothelial growth factor, which likely contributes to hypoxia-induced extravasation of fluid and leukocytes. We conclude that ANXA2 contributes to pulmonary microvascular integrity by enabling VEC-related phosphatase activity, thereby preventing vascular leak during alveolar hypoxia.
- 10 July 2017
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 214 (9) , 2535-2545
Open AccessAnnexin A2 supports pulmonary microvascular integrity by linking vascular endothelial cadherin and protein tyrosine phosphatases
Relative or absolute hypoxia activates signaling pathways that alter gene expression and stabilize the pulmonary microvasculature. Alveolar hypoxia occurs in disorders ranging from altitude sickness to airway obstruction, apnea, and atelectasis. Here, we report that the phospholipid-binding protein, annexin A2 (ANXA2) functions to maintain vascular integrity in the face of alveolar hypoxia. We demonstrate that microvascular endothelial cells (ECs) from Anxa2−/− mice display reduced barrier function and excessive Src-related tyrosine phosphorylation of the adherens junction protein vascular endothelial cadherin (VEC). Moreover, unlike Anxa2+/+ controls, Anxa2−/− mice develop pulmonary edema and neutrophil infiltration in the lung parenchyma in response to subacute alveolar hypoxia. Mice deficient in the ANXA2-binding partner, S100A10, failed to demonstrate hypoxia-induced pulmonary edema under the same conditions. Further analyses reveal that ANXA2 forms a complex with VEC and its phosphatases, EC-specific protein tyrosine phosphatase (VE-PTP) and Src homology phosphatase 2 (SHP2), both of which are implicated in vascular integrity. In the absence of ANXA2, VEC is hyperphosphorylated at tyrosine 731 in response to vascular endothelial growth factor, which likely contributes to hypoxia-induced extravasation of fluid and leukocytes. We conclude that ANXA2 contributes to pulmonary microvascular integrity by enabling VEC-related phosphatase activity, thereby preventing vascular leak during alveolar hypoxia.